The administration launched TrumpRx, a consumer-facing portal powered by GoodRx technology to display cash prices for prescription drugs and direct patients to purchase options. Officials pitched the site as a tool to improve price transparency and patient access, while analysts caution it may not by itself materially lower net drug costs. The rollout is tightly linked to ongoing policy discussions on PBM reform and Medicare drug negotiation measures included in the recent funding package. Industry players and payers will monitor whether public visibility of cash prices alters prescribing behavior or manufacturer pricing strategies.